SCHEMBL5448351

SCHEMBL5448351

NC(=O)c1c(NC(=O)Nc2cccc(I)c2)sc2c1CCOC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.55
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
EPHB4 P54760 1/20 0.51
KCNH2 Q12809 4/20 0.48
TNIK Q9UKE5 1/20 0.47
CNR2 P34972 3/20 0.45
CXCR2 P25025 2/20 0.45
CNR1 P21554 2/20 0.45
PTPRC P08575 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPRB P23467 1/20 0.45
PTPRE P23469 1/20 0.45
ANO1 Q5XXA6 4/20 0.44
RAB7A P51149 1/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467205 0.89 CFTR (0.56) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5451652 0.88 CFTR (0.60) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5457654 0.88 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5454365 0.88 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5455947 0.87 MEN1 (0.65) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5466862 0.87 CFTR (0.57) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5449672 0.85 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5458044 0.85 CFTR (0.57) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5455489 0.85 CFTR (0.55) CFTRMEN1KMT2ANPC1RAB9A
SCHEMBL5453563 0.85 CFTR (0.52) CFTRMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.